Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809662 · ClinicalTrials.gov registry record
Comparing Immune Responses to Topical Imiquimod
A clinical trial, sponsored by University of California, Davis.
- Terminated
- Registry status
- 6
- Enrollment target
NCT04809662: Clinical Trial study, sponsored by University of California, Davis.
NCT04809662 is a clinical trial that was terminated before completion, run by University of California, Davis. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04809662 was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.
Primary Outcome
RNA sequencing of patients to gauge immune response as measured by expression of key inflammatory cytokines related to TLR7 response generated by imiquimod.
Interventions
- DRUG Imiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2023-11-07 |
Why NCT04809662 stopped before completion
NCT04809662 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Imiquimod is the first listed.
NCT04809662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04809662 about?
NCT04809662 is a clinical study titled "Comparing Immune Responses to Topical Imiquimod". The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after applicati...
What is the current status of trial NCT04809662?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2021-03-16. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT04809662?
The interventions under investigation include: Imiquimod (DRUG).
Who is sponsoring clinical trial NCT04809662?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI